Studies in Kenya and Cuba
photo by Nurjannah Ahmat


Click here to download the full report [PDF 2.6MB]

A new remedy, called Iquilai, has been developed in the search for a treatment for the devastating effects of the disease AIDS. This remedy is homeopathic in origin and focuses on restoring the patient’s damaged immune system. It had shown very impressive clinical improvements in patients treated earlier. To study the effect in patients infected with HIV, a pilot study was conducted in Kenya.

A total of 228 HIV-positive patients formed a group of AIDS patients in different stages of the disease.Patients in the advanced or very advanced stage of the WHO classification (CD4 <200) formed 78% of the total tested group. (59% of the patients had CD4 tested) About half the patients were already using regular anti-retroviral treatment (ART-monotherapy). The patients who did not get ART had a CD4 cell count >200, were not tested yet or had no acces to regular treatment. Also individual patients had stopped ART because of the side effects. Each patient was given a total of five doses of the Iquilai remedy over a period of five consecutive days. The follow-up was recorded over a period of between four and nine months. Clinical parameters as well as the laboratory results of the CD4 cell count were recorded. As a primary outcome the Karnofsky score was taken, as in earlier treated patients the clinical improvement was very impressive. The CD4 was tested to see if the improvement could also be seen in laboratory tests. It was tested only in about 59% of the patients out of cost considerations. For the same reason no viral load was tested.

The results of this pilot study in the treatment of HIV/AIDS are as follows:

  • More than 90% of the patients had a positive response to the remedy, defined as an increase of 10 points or more on the Karnofsky score. 68% had an increase of 20 points or more.
  • There was a strong improvement in their health status. Opportunistic infections healed without further intervention.
  • 65% of the patients were requiring assistance (Karnofsky score < = 60) and changed their status to being able to perform their normal duties again.(Karnofsky>80)
  • The CD4 cell values of the tested group showed significant increases.(average of 123 points).
  • Side effects from regular ART were reduced.



In September 2011 a RCT (randomized controlled trial) began in Cuba. The trial focuses on the effect of Iquilai, placebo controlled, in 300 patients infected with HIV. The group is selected according to the regulations of the ethical committee, in compliance with the Declaration of Helsinki. The trial is organized and supported by the government, in collaboration with Aids Remedy Fund, according to the highest standards of scientific research, a standard which Cuba is well known for. To explore the therapeutic effectiveness of Iquilai, it will be compared with a placebo; however the patients will be maintained under antiretroviral treatment as needed. The Iquilai or placebo treatment will be only an additional or complementary treatment. 

Design of the study 

The Clinical Trial consist in a Phase III, multicenter, randomized, controlled against placebo and blind double study, with 2 groups in parallel: a group will be treated with Iquilai according to the schedule during 6 months, and another group will receive a placebo with the same frequency.